FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667583> ?p ?o ?g. }

• W4385667583 endingPage "e23759a8" @default.
• W4385667583 startingPage "e23759a8" @default.
• W4385667583 abstract "Topic: 35. Quality of life and palliative care Background: Polycythemia vera (PV) is associated with troublesome symptoms and reduced quality of life (QoL). Although its treatment is risk-adapted and aims to minimize or improve symptoms, symptom burden is not included as a risk stratification factor for PV. Symptom burden and its impact on QoL may be underestimated in “low risk” patients (with age <60 and without prior thrombo-hemorrhagic events). Aims: The study, therefore, aimed to explore symptom burden and QoL in “low risk” PV patients and to compare such aspects with that in “high risk” PV. Methods: Patients with PV were selected from a cohort of participated in a cross-sectional nationwide survey MPN-QoL-2020 carried out in September-December 2020 in different areas of Russia. Patients aged ≥18 years with a confirmed diagnosis of PV and treated on the in-patient or outpatient basis were included in the analysis. For symptom and QoL assessment MPN10 and HM-PRO were used, respectively. The MPN10 assesses 10 of the most clinically relevant symptoms, including fatigue and generates a Total Symptom Score (TSS). The HM-PRO is a specific QoL questionnaire for patients with hematologic malignancies developed for the use in clinical practice. It consists of two scales: Part A measuring the ‘impact on patients’ QoL’; Part B – ‘signs and symptoms’ (S&S) experienced by the patients. Part A has 4 domains: physical behavior (PB), social well-being (SW), emotional behavior (EB), eating and drinking habits (ED). Higher scores indicate greater impact. Exploratory analyses were carried out applying descriptive statistics, χ2 test and Mann-Whitney U test. Results: Altogether 265 PV patients were included in the analysis: 95 patients were identified as “low risk” (mean age±SD – 48.8±11.6 yrs; 49.5% males) and 170 patients as “high risk” PV (mean age – 62.9±12.3 yrs; 45.3% males). In the “low risk” group, 69.5% received cytoreductive treatments (CT) – hydrea (64%), interferons (30%), ruxolitinib (6%); in the high risk group, 86.5% received CT – hydrea (79%), interferons (15%), ruxolitinib (6%). Among “low risk” PV, 94.7% reported at least 1 PV-related symptom. The most frequently reported symptoms of MPN10 were inactivity (83%), fatigue (81%) and itching (65%). Symptoms with the highest reported mean severity scores were fatigue (3.3±2.6), inactivity (3.3±2.6), problems concentrating (2.8±2.9) and itching (2.6±2.9). More than half of “low risk” patients (61.5%) experienced moderate-to-severe symptoms (4-10 scores). Symptom burden according to MPN10 TSS was similar to “high risk” patients: 20.4±16.5 vs 24.6±18.4 (ns). Prevalence of moderate-to-severe symptoms did not differ significantly between “low risk” (61.5%) and “high risk” (71.7%) PV (ns). In “low risk” PV, the highest impact on QoL by HM-PRO (Part A) was for EB (Table). According to HM-PRO Part A and S&S, 26.3% and 44.2% patients exhibited moderate/very large/extremely large effect on QoL and S&S, respectively (Table). In “high risk” PV these proportions were 38.2% and 52.3%, respectively (ns). QoL impact and S&S were higher in “high risk” than in “low risk” PV (p<0.05), Table. Summary/Conclusion: In conclusion, the vast majority of patients with “low risk” PV reported high PV-related symptoms/ symptom burden and impact on QoL. Further prospective studies are worthwhile to explore the determinants of symptom burden in “low risk” PV. Furthermore, the results suggest that risk profiling may not capture all aspects of disease burden in PV and this highlights the importance of using patient-reported outcomes, namely MPN10 and HM-PRO, to identify unmet patients’ needs, especially in “low risk” PV.Keywords: Risk factor, Quality of life, Polycythemia vera" @default.
• W4385667583 created "2023-08-09" @default.
• W4385667583 creator A5000837595 @default.
• W4385667583 creator A5002853101 @default.
• W4385667583 creator A5005032616 @default.
• W4385667583 creator A5008829798 @default.
• W4385667583 creator A5011488783 @default.
• W4385667583 creator A5014159162 @default.
• W4385667583 creator A5015497219 @default.
• W4385667583 creator A5016972232 @default.
• W4385667583 creator A5023446963 @default.
• W4385667583 creator A5024179923 @default.
• W4385667583 creator A5025632705 @default.
• W4385667583 creator A5026283466 @default.
• W4385667583 creator A5026966661 @default.
• W4385667583 creator A5027516224 @default.
• W4385667583 creator A5028226591 @default.
• W4385667583 creator A5030468887 @default.
• W4385667583 creator A5035629448 @default.
• W4385667583 creator A5037093540 @default.
• W4385667583 creator A5041155630 @default.
• W4385667583 creator A5042699620 @default.
• W4385667583 creator A5045521949 @default.
• W4385667583 creator A5046033918 @default.
• W4385667583 creator A5046838777 @default.
• W4385667583 creator A5047517087 @default.
• W4385667583 creator A5047653556 @default.
• W4385667583 creator A5052005638 @default.
• W4385667583 creator A5055375632 @default.
• W4385667583 creator A5062953037 @default.
• W4385667583 creator A5065169573 @default.
• W4385667583 creator A5065776788 @default.
• W4385667583 creator A5067552999 @default.
• W4385667583 creator A5067939365 @default.
• W4385667583 creator A5068614681 @default.
• W4385667583 creator A5069763928 @default.
• W4385667583 creator A5074203426 @default.
• W4385667583 creator A5074356444 @default.
• W4385667583 creator A5077149193 @default.
• W4385667583 creator A5077189736 @default.
• W4385667583 creator A5078634760 @default.
• W4385667583 creator A5079649774 @default.
• W4385667583 creator A5081306441 @default.
• W4385667583 creator A5084240197 @default.
• W4385667583 date "2023-08-01" @default.
• W4385667583 modified "2023-10-14" @default.
• W4385667583 title "P1692: UNMET NEEDS IN PATIENTS WITH “LOW RISK” POLYCYTHEMIA VERA (PV): SYMPTOM BURDEN AND QUALITY OF LIFE" @default.
• W4385667583 doi "https://doi.org/10.1097/01.hs9.0000973640.23759.a8" @default.
• W4385667583 hasPublicationYear "2023" @default.
• W4385667583 type Work @default.
• W4385667583 citedByCount "0" @default.
• W4385667583 crossrefType "journal-article" @default.
• W4385667583 hasAuthorship W4385667583A5000837595 @default.
• W4385667583 hasAuthorship W4385667583A5002853101 @default.
• W4385667583 hasAuthorship W4385667583A5005032616 @default.
• W4385667583 hasAuthorship W4385667583A5008829798 @default.
• W4385667583 hasAuthorship W4385667583A5011488783 @default.
• W4385667583 hasAuthorship W4385667583A5014159162 @default.
• W4385667583 hasAuthorship W4385667583A5015497219 @default.
• W4385667583 hasAuthorship W4385667583A5016972232 @default.
• W4385667583 hasAuthorship W4385667583A5023446963 @default.
• W4385667583 hasAuthorship W4385667583A5024179923 @default.
• W4385667583 hasAuthorship W4385667583A5025632705 @default.
• W4385667583 hasAuthorship W4385667583A5026283466 @default.
• W4385667583 hasAuthorship W4385667583A5026966661 @default.
• W4385667583 hasAuthorship W4385667583A5027516224 @default.
• W4385667583 hasAuthorship W4385667583A5028226591 @default.
• W4385667583 hasAuthorship W4385667583A5030468887 @default.
• W4385667583 hasAuthorship W4385667583A5035629448 @default.
• W4385667583 hasAuthorship W4385667583A5037093540 @default.
• W4385667583 hasAuthorship W4385667583A5041155630 @default.
• W4385667583 hasAuthorship W4385667583A5042699620 @default.
• W4385667583 hasAuthorship W4385667583A5045521949 @default.
• W4385667583 hasAuthorship W4385667583A5046033918 @default.
• W4385667583 hasAuthorship W4385667583A5046838777 @default.
• W4385667583 hasAuthorship W4385667583A5047517087 @default.
• W4385667583 hasAuthorship W4385667583A5047653556 @default.
• W4385667583 hasAuthorship W4385667583A5052005638 @default.
• W4385667583 hasAuthorship W4385667583A5055375632 @default.
• W4385667583 hasAuthorship W4385667583A5062953037 @default.
• W4385667583 hasAuthorship W4385667583A5065169573 @default.
• W4385667583 hasAuthorship W4385667583A5065776788 @default.
• W4385667583 hasAuthorship W4385667583A5067552999 @default.
• W4385667583 hasAuthorship W4385667583A5067939365 @default.
• W4385667583 hasAuthorship W4385667583A5068614681 @default.
• W4385667583 hasAuthorship W4385667583A5069763928 @default.
• W4385667583 hasAuthorship W4385667583A5074203426 @default.
• W4385667583 hasAuthorship W4385667583A5074356444 @default.
• W4385667583 hasAuthorship W4385667583A5077149193 @default.
• W4385667583 hasAuthorship W4385667583A5077189736 @default.
• W4385667583 hasAuthorship W4385667583A5078634760 @default.
• W4385667583 hasAuthorship W4385667583A5079649774 @default.
• W4385667583 hasAuthorship W4385667583A5081306441 @default.
• W4385667583 hasAuthorship W4385667583A5084240197 @default.
• W4385667583 hasBestOaLocation W43856675831 @default.
• W4385667583 hasConcept C126322002 @default.
• W4385667583 hasConcept C159110408 @default.
• W4385667583 hasConcept C1862650 @default.

• next